Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 31, 2018

Conditions
Epidermolysis Bullosa Simplex
Interventions
DRUG

diacerein 1% ointment

diacerein 1% ointment administered topically

DRUG

A placebo ointment

vehicle ointment administered topically

Trial Locations (22)

2217

Premier Specialists Pty Ltd; The Church, Kogarah

11790

Stony Brook University Medical Center, Stony Brook

27516

University of North Carolina - Chapel Hill, Chapel Hill

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55455

University of Minnesota, Minneapolis

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

Northwestern University, Chicago

65212

University of Missouri Healthcare, Columbia

75010

Hopital Saint Louis, Paris

75015

Hopital Necker-Enfants Malades, Paris

78218

Children's Hospital of San Antonio ; Texas Dermatology and Laser Specialists, San Antonio

79104

University Medical Center Freiburg, Freiburg im Breisgau

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Childrens Hospital, Phoenix

94304

Stanford University, Palo Alto

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

29425-5780

Medical University of South Carolina (MUSC), Charleston

A-5020

EB House Austria, Salzburg

06202

CHU de NICE - Hopital de l'Archet II - Service de Dermatologie, Nice

AB20;30,001

University Medical Center Groningen, Groningen

WC1N 3JH

Great Ormond Street Hospital, London

SE1 7EH

St. Thomas' Hospital - St Johns Institute of Dermatology, London

All Listed Sponsors
lead

Castle Creek Pharmaceuticals, LLC

INDUSTRY